Which stimulant medication is preferred for each age group (children 6‑12, adolescents 13‑17, adults 18‑64, and adults >65)?

Best Stimulant Medication by Age Group

For children ages 6-12, methylphenidate is the preferred first-line stimulant; for adolescents 13-17, methylphenidate remains first-line with special consideration for abuse-deterrent formulations; for adults 18-64, amphetamines are the preferred first-choice; and for adults >65, there is insufficient evidence to make age-specific recommendations, though methylphenidate may be preferred given its shorter half-life and lower cardiovascular burden. 1

Children Ages 6-12 Years

Methylphenidate should be the first-line stimulant for school-age children. 2, 1

• The 2018 Lancet network meta-analysis of 133 randomized controlled trials found methylphenidate superior to placebo with an SMD of -0.78 (95% CI -0.93 to -0.62) based on clinician ratings, and importantly, methylphenidate was one of only two medications showing efficacy on teacher ratings (SMD -0.82,95% CI -1.16 to -0.48). 1

• Starting dose is 5 mg given after breakfast and lunch, with titration in weekly increments of 5-10 mg per dose until symptom control is achieved or side effects emerge. 2

• Maximum total daily dose is 60 mg per the PDR, though expert consensus suggests limiting to 40 mg total daily when using multiple doses throughout the day. 2

• Children weighing less than 25 kg should not receive single doses greater than 15 mg of methylphenidate. 2

If methylphenidate fails or is not tolerated, amphetamines (dextroamphetamine or mixed amphetamine salts) are the second choice. 2, 1

• Starting dose is 2.5 mg, with titration in 2.5-5 mg increments. 2

• Maximum total daily dose is 40 mg. 2

• Amphetamines have greater problematic effects on appetite and sleep compared to methylphenidate, consistent with their longer excretion half-lives. 2

• In head-to-head comparisons, amphetamines showed superior efficacy over methylphenidate in children (SMD differences of -0.24 to -0.46), but tolerability concerns favor methylphenidate as first-line. 1

Adolescents Ages 13-17 Years

Methylphenidate remains the preferred first-line stimulant for adolescents, with special consideration for abuse-deterrent formulations. 2, 1

• The same efficacy and dosing principles apply as for children ages 6-12. 2

• Diversion and misuse are major concerns in this age group, warranting consideration of formulations with lower abuse potential: lisdexamfetamine (requires metabolic activation by erythrocytes), dermal methylphenidate patches, or OROS methylphenidate (extraction-resistant). 2

• Clinicians must monitor prescription-refill requests for signs of misuse or diversion. 2

• Before initiating stimulants in newly diagnosed adolescents, assess for substance abuse symptoms; when present, assessment off substances should precede ADHD treatment. 2

• Medication coverage should extend to driving hours given the inherent risks of driving with untreated ADHD in adolescents. 2

Adults Ages 18-64 Years

Amphetamines are the preferred first-choice stimulant for adults based on superior efficacy. 1

• The 2018 Lancet meta-analysis found amphetamines significantly more efficacious than methylphenidate in adults, with an SMD of -0.79 (95% CI -0.99 to -0.58) for amphetamines versus -0.49 (95% CI -0.64 to -0.35) for methylphenidate. 1

• In direct head-to-head comparisons, amphetamines were superior to methylphenidate in adults with SMD differences of -0.29 to -0.94. 1

• However, amphetamines have inferior tolerability compared to placebo in adults (OR 3.26,95% CI 1.54-6.92), as do methylphenidate (OR 2.39,95% CI 1.40-4.08) and atomoxetine (OR 2.33,95% CI 1.28-4.25). 1

• Adults on stimulants should have blood pressure and pulse checked quarterly by the treating or primary care physician. 2

• Starting doses follow the same principles as children: 5 mg for methylphenidate or 2.5 mg for amphetamines, with similar titration schedules. 2

Adults >65 Years

There is no high-quality evidence specifically addressing stimulant choice in older adults, but methylphenidate may be preferred over amphetamines due to its shorter half-life and potentially lower cardiovascular burden. 2

• The available guidelines do not provide age-specific recommendations for adults over 65, as this population was largely excluded from clinical trials. 2, 1

• Cardiovascular monitoring is critical: baseline and quarterly blood pressure and pulse checks are essential to identify essential hypertension and cardiac arrhythmias. 2

• Lower starting doses and slower titration are prudent given age-related changes in drug metabolism and increased cardiovascular risk. 2

• Methylphenidate's shorter duration of action may allow for better management of side effects and cardiovascular parameters in this vulnerable population. 2

Special Considerations Across All Ages

Pemoline should not be used due to risk of hepatic failure and death. 2

• Although effective, pemoline has caused 13 cases of total liver failure since introduction, with 11 resulting in death or transplantation within 4 weeks. 2

• This rate is 4-17 times higher than expected in the normal population. 2

Non-stimulants (atomoxetine, guanfacine, clonidine) are generally second-line across all age groups due to smaller effect sizes compared to stimulants. 2, 1

• Non-stimulants may be considered first-line in specific comorbidities: substance use disorders, tic/Tourette's disorder, or disruptive behavior disorders. 2

• Onset of effect is delayed: 6-12 weeks for atomoxetine, 2-4 weeks for guanfacine and clonidine. 2